Time point | Study period | ||||||
---|---|---|---|---|---|---|---|
Enrolment | Baseline | Injection | Post-allocation | Close-out | |||
1 | 1 M | 3 M | 6 M | 12 M | |||
Enrolment | |||||||
Eligibility screen | × | ||||||
Informed consent | × | ||||||
Allocation | × | ||||||
Interventions: | |||||||
Platelet rich plasma | × | ||||||
Saline | × | ||||||
Assessments: | |||||||
Primary outcomes | |||||||
aWOMAC score | × | × | × | × | × | ||
Secondary outcomes | |||||||
bVAS | × | × | × | × | × | ||
Lysholm score | × | × | × | × | × | ||
cSF-36 | × | × | × | × | × | ||
MRI analysis | × | × | |||||
Other measures | |||||||
Drug/supplement use | × | × | × | × | × | ||
Platelets and leukocytes counts, VEGF and TGF-β | × | ||||||
Number of injections | × | ||||||
Adverse events | × | × | × | × | × | ||
Success of blinding | × | ||||||
Descriptive measures | |||||||
Weight, height, BMI, Kellgren and Lawrence grade, Age, gender, duration of symptoms | × | ||||||
Injection site, Complications | × |